JP2014509313A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014509313A5 JP2014509313A5 JP2013552124A JP2013552124A JP2014509313A5 JP 2014509313 A5 JP2014509313 A5 JP 2014509313A5 JP 2013552124 A JP2013552124 A JP 2013552124A JP 2013552124 A JP2013552124 A JP 2013552124A JP 2014509313 A5 JP2014509313 A5 JP 2014509313A5
- Authority
- JP
- Japan
- Prior art keywords
- nasal
- nose
- powder
- ingested
- sucking
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000001331 nose Anatomy 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102011009961A DE102011009961A1 (de) | 2011-02-01 | 2011-02-01 | 7-Azaindolderivate |
| DE102011009961.1 | 2011-02-01 | ||
| PCT/EP2012/000067 WO2012104007A2 (de) | 2011-02-01 | 2012-01-09 | 7-azaindolderivate |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014509313A JP2014509313A (ja) | 2014-04-17 |
| JP2014509313A5 true JP2014509313A5 (enExample) | 2016-01-21 |
| JP5891249B2 JP5891249B2 (ja) | 2016-03-22 |
Family
ID=45554609
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013552124A Expired - Fee Related JP5891249B2 (ja) | 2011-02-01 | 2012-01-09 | ７−アザインドール誘導体 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US8981101B2 (enExample) |
| EP (3) | EP2746281B1 (enExample) |
| JP (1) | JP5891249B2 (enExample) |
| KR (1) | KR20140014158A (enExample) |
| CN (3) | CN103502247B (enExample) |
| AR (1) | AR085110A1 (enExample) |
| AU (1) | AU2012213775B2 (enExample) |
| BR (1) | BR112013019028A2 (enExample) |
| CA (2) | CA2826051C (enExample) |
| DE (1) | DE102011009961A1 (enExample) |
| EA (1) | EA201300873A1 (enExample) |
| ES (3) | ES2861048T3 (enExample) |
| HK (1) | HK1226394A1 (enExample) |
| IL (1) | IL227689A0 (enExample) |
| MX (1) | MX2013008212A (enExample) |
| SG (1) | SG192133A1 (enExample) |
| WO (1) | WO2012104007A2 (enExample) |
| ZA (1) | ZA201306542B (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102958930B (zh) * | 2010-06-28 | 2018-04-27 | 默克专利有限公司 | 作为用于对抗癌症的激酶抑制剂的2,4-二芳基取代的[1,8]二氮杂萘化合物 |
| DE102010053347A1 (de) * | 2010-12-03 | 2012-06-06 | Merck Patent Gmbh | 3-Hetaryl-substituierte Pyrrolo[2,3-b] pyridin-derivative als PDK1-Inhibitoren |
| DE102011009961A1 (de) * | 2011-02-01 | 2012-08-02 | Merck Patent Gmbh | 7-Azaindolderivate |
| US20150038527A1 (en) * | 2012-02-21 | 2015-02-05 | Merck Patent Gmbh | Furopyridine derivatives |
| DE102012019369A1 (de) | 2012-10-02 | 2014-04-03 | Merck Patent Gmbh | 7-Azaindolderivat |
| FR3001219A1 (fr) * | 2013-01-22 | 2014-07-25 | Centre Nat Rech Scient | Inhibiteurs de kinases |
| GB201303109D0 (en) | 2013-02-21 | 2013-04-10 | Domainex Ltd | Novel pyrimidine compounds |
| US20140303121A1 (en) | 2013-03-15 | 2014-10-09 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
| NZ630875A (en) * | 2013-03-15 | 2017-12-22 | Plexxikon Inc | Heterocyclic compounds and uses thereof |
| TW201613916A (en) | 2014-06-03 | 2016-04-16 | Gilead Sciences Inc | TANK-binding kinase inhibitor compounds |
| KR101949624B1 (ko) | 2014-09-26 | 2019-02-18 | 길리애드 사이언시즈, 인코포레이티드 | Tank-결합 키나제 억제제 화합물로서 유용한 아미노트리아진 유도체 |
| US10875844B2 (en) | 2015-03-04 | 2020-12-29 | Dana-Farber Cancer Institute, Inc. | Salicylate inhibitors of MELK and methods of use |
| US10160755B2 (en) | 2015-04-08 | 2018-12-25 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| AU2016287335B2 (en) * | 2015-06-29 | 2020-01-23 | Merck Patent Gmbh | TBK/IKKepsilon inhibitor compounds and uses thereof |
| WO2017106556A1 (en) | 2015-12-17 | 2017-06-22 | Gilead Sciences, Inc. | Tank-binding kinase inhibitor compounds |
| EP3390387B1 (en) | 2015-12-18 | 2021-11-17 | Bayer Pharma Aktiengesellschaft | Heteroarylbenzimidazole compounds |
| CN105906608B (zh) * | 2016-05-03 | 2018-10-19 | 中山大学 | 8-氨基喹啉-松果体素杂联体及其药物组合物 |
| WO2017207534A1 (en) | 2016-06-03 | 2017-12-07 | Bayer Pharma Aktiengesellschaft | Substituted heteroarylbenzimidazole compounds |
| GB201702947D0 (en) | 2017-02-23 | 2017-04-12 | Domainex Ltd | Novel compounds |
| CN110461841B (zh) * | 2017-06-19 | 2020-09-15 | 上海和誉生物医药科技有限公司 | 一种具有csf1r抑制活性的氮杂芳基衍生物、其制备方法和应用 |
| AU2018348241B2 (en) | 2017-10-13 | 2023-01-12 | Opna Bio SA | Solid forms of a compound for modulating kinases |
| CN112839648B (zh) * | 2018-06-07 | 2025-04-04 | 达萨玛治疗公司 | Sarm1抑制剂 |
| ES3028093T3 (en) | 2018-06-07 | 2025-06-18 | Disarm Therapeutics Inc | Inhibitors of sarm1 |
| KR20200046680A (ko) * | 2018-10-25 | 2020-05-07 | 한국과학기술원 | Pdk1 저해제를 포함하는 역노화 유도용 조성물 |
| WO2025016273A1 (zh) * | 2023-07-14 | 2025-01-23 | 拜西欧斯（北京）生物技术有限公司 | 异喹啉衍生物、包含其的药物组合物以及它们的用途 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5747469A (en) | 1991-03-06 | 1998-05-05 | Board Of Regents, The University Of Texas System | Methods and compositions comprising DNA damaging agents and p53 |
| GB9904387D0 (en) | 1999-02-25 | 1999-04-21 | Pharmacia & Upjohn Spa | Antitumour synergistic composition |
| AU5213300A (en) | 1999-05-19 | 2000-12-12 | Smithkline Beecham Plc | 2-nh-pyridones and pyrimidones as mrs inhibitors |
| WO2005047266A1 (en) * | 2003-11-14 | 2005-05-26 | Lorus Therapeutics Inc. | Aryl imidazoles and their use as anti-cancer agents |
| SE0303180D0 (sv) * | 2003-11-26 | 2003-11-26 | Astrazeneca Ab | Novel compounds |
| UA87494C2 (en) * | 2004-03-30 | 2009-07-27 | Вертекс Фармасьютикалс Инкорпорейтед | Azaindoles useful as inhibitors of jak and other protein kinases |
| CA2560454C (en) | 2004-03-30 | 2013-05-21 | Vertex Pharmaceuticals Incorporated | Azaindoles useful as inhibitors of jak and other protein kinases |
| FR2868422B1 (fr) | 2004-03-31 | 2006-07-14 | Aventis Pharma Sa | Nouveaux derives pyrrolo(2,3-b) pyridine, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases |
| US20080153869A1 (en) * | 2004-06-14 | 2008-06-26 | Bressi Jerome C | Kinase Inhibitors |
| US7709645B2 (en) | 2004-07-27 | 2010-05-04 | Sgx Pharmaceuticals, Inc. | Pyrrolo-pyridine kinase modulators |
| WO2006050076A1 (en) * | 2004-10-29 | 2006-05-11 | Janssen Pharmaceutica, N.V. | Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders |
| WO2006052568A2 (en) | 2004-11-10 | 2006-05-18 | Eli Lilly And Company | Tgf-beta inhibitors |
| EP1828180A4 (en) * | 2004-12-08 | 2010-09-15 | Glaxosmithkline Llc | 1H-pyrrolo [2,3-BETA] PYRIDINE |
| US20090275570A1 (en) | 2005-04-06 | 2009-11-05 | Astrazeneca Ab | Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors |
| WO2006130673A1 (en) * | 2005-05-31 | 2006-12-07 | Janssen Pharmaceutica, N.V. | 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders |
| JP2007099640A (ja) | 2005-09-30 | 2007-04-19 | Tsumura & Co | 含窒素複素環化合物、その製造方法およびそれを用いた医薬組成物 |
| CN101374839A (zh) * | 2006-01-17 | 2009-02-25 | 沃泰克斯药物股份有限公司 | 适用作詹纳斯激酶抑制剂的吖吲哚类 |
| EP2537849A3 (en) * | 2006-01-17 | 2013-04-03 | Vertex Pharmaceuticals, Inc. | Azaindoles useful as inhibitors of janus kinases |
| DE102006012617A1 (de) | 2006-03-20 | 2007-09-27 | Merck Patent Gmbh | 4-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate |
| US20100267707A1 (en) | 2006-06-22 | 2010-10-21 | Merck Sharp & Dohme Corp. | Tyrosine Kinase Inhibitors |
| EP2038272B8 (en) | 2006-06-30 | 2013-10-23 | Sunesis Pharmaceuticals, Inc. | Pyridinonyl pdk1 inhibitors |
| CA2673003A1 (en) | 2006-12-22 | 2008-07-03 | Novartis Ag | Quinazolines for pdk1 inhibition |
| AU2008226844A1 (en) | 2007-03-13 | 2008-09-18 | Merck Sharp & Dohme Corp. | Inhibitors of janus kinases and/or 3-phosphoinositide-dependent protein kinase-1 |
| AU2008266883B2 (en) | 2007-06-20 | 2014-01-30 | Merck Sharp & Dohme Corp. | Inhibitors of janus kinases |
| DE102007028515A1 (de) * | 2007-06-21 | 2008-12-24 | Merck Patent Gmbh | 6-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate |
| WO2009054941A1 (en) | 2007-10-25 | 2009-04-30 | Merck & Co., Inc. | Therapeutic compounds |
| RU2503676C2 (ru) * | 2008-02-25 | 2014-01-10 | Ф.Хоффманн-Ля Рош Аг | Пирролопиразиновые ингибиторы киназы |
| DE102008025751A1 (de) * | 2008-05-29 | 2009-12-03 | Merck Patent Gmbh | 4-(1H-Pyrrolo[2,3-b]pyridin-3-yl)-pyridin-2-ylamin-derivate |
| DE102008031517A1 (de) | 2008-07-03 | 2010-01-07 | Merck Patent Gmbh | Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate |
| DE102008038221A1 (de) * | 2008-08-18 | 2010-02-25 | Merck Patent Gmbh | 7-Azaindolderivate |
| CN101723936B (zh) | 2008-10-27 | 2014-01-15 | 上海睿星基因技术有限公司 | 激酶抑制剂及其在药学中的用途 |
| DE102009019962A1 (de) | 2009-05-05 | 2010-11-11 | Merck Patent Gmbh | 3-([1,2,3]Triazol-4-yl)-pyrrolo[2,3-b]pyridinderivate |
| WO2011149950A2 (en) * | 2010-05-24 | 2011-12-01 | University Of Rochester | Bicyclic heteroaryl kinase inhibitors and methods of use |
| CN102958930B (zh) * | 2010-06-28 | 2018-04-27 | 默克专利有限公司 | 作为用于对抗癌症的激酶抑制剂的2,4-二芳基取代的[1,8]二氮杂萘化合物 |
| DE102010053347A1 (de) | 2010-12-03 | 2012-06-06 | Merck Patent Gmbh | 3-Hetaryl-substituierte Pyrrolo[2,3-b] pyridin-derivative als PDK1-Inhibitoren |
| DE102011009961A1 (de) * | 2011-02-01 | 2012-08-02 | Merck Patent Gmbh | 7-Azaindolderivate |
-
2011
- 2011-02-01 DE DE102011009961A patent/DE102011009961A1/de not_active Withdrawn
-
2012
- 2012-01-09 ES ES16002047T patent/ES2861048T3/es active Active
- 2012-01-09 AU AU2012213775A patent/AU2012213775B2/en not_active Ceased
- 2012-01-09 US US13/983,083 patent/US8981101B2/en not_active Expired - Fee Related
- 2012-01-09 ES ES12701437.1T patent/ES2608317T3/es active Active
- 2012-01-09 JP JP2013552124A patent/JP5891249B2/ja not_active Expired - Fee Related
- 2012-01-09 WO PCT/EP2012/000067 patent/WO2012104007A2/de not_active Ceased
- 2012-01-09 CA CA2826051A patent/CA2826051C/en not_active Expired - Fee Related
- 2012-01-09 CN CN201280007145.3A patent/CN103502247B/zh not_active Expired - Fee Related
- 2012-01-09 EP EP14000623.0A patent/EP2746281B1/de not_active Not-in-force
- 2012-01-09 BR BR112013019028A patent/BR112013019028A2/pt not_active IP Right Cessation
- 2012-01-09 CA CA3082435A patent/CA3082435A1/en not_active Abandoned
- 2012-01-09 KR KR1020137022887A patent/KR20140014158A/ko not_active Withdrawn
- 2012-01-09 CN CN201610048667.8A patent/CN105732617B/zh not_active Expired - Fee Related
- 2012-01-09 SG SG2013056726A patent/SG192133A1/en unknown
- 2012-01-09 EP EP16002047.5A patent/EP3133074B1/de not_active Not-in-force
- 2012-01-09 EP EP12701437.1A patent/EP2670748B1/de not_active Not-in-force
- 2012-01-09 ES ES14000623.0T patent/ES2634643T3/es active Active
- 2012-01-09 CN CN201610048764.7A patent/CN105712991B/zh not_active Expired - Fee Related
- 2012-01-09 EA EA201300873A patent/EA201300873A1/ru unknown
- 2012-01-09 MX MX2013008212A patent/MX2013008212A/es not_active Application Discontinuation
- 2012-02-01 AR ARP120100332A patent/AR085110A1/es not_active Application Discontinuation
-
2013
- 2013-07-29 IL IL227689A patent/IL227689A0/en active IP Right Grant
- 2013-08-30 ZA ZA2013/06542A patent/ZA201306542B/en unknown
-
2015
- 2015-02-06 US US14/616,113 patent/US9266887B2/en not_active Expired - Fee Related
-
2016
- 2016-01-05 US US14/987,946 patent/US9725446B2/en not_active Expired - Fee Related
- 2016-12-23 HK HK16114637.2A patent/HK1226394A1/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014509313A5 (enExample) | ||
| JP2013534227A5 (enExample) | ||
| JP2014526447A5 (enExample) | ||
| JP2013544781A5 (enExample) | ||
| JP2013541565A5 (enExample) | ||
| JP2015505541A5 (enExample) | ||
| Doktorovova et al. | Preclinical safety of solid lipid nanoparticles and nanostructured lipid carriers: Current evidence from in vitro and in vivo evaluation | |
| EA201590286A1 (ru) | Аэрозольное ингаляционное устройство | |
| RU2015121091A (ru) | Порошки для ингаляции с ультранизкой плотностью | |
| MX371521B (es) | Sistema de inhalacion de polvo seco. | |
| EA201591729A1 (ru) | Пригодные для вдыхания агломераты частиц пористого носителя и тонкоизмельченного лекарственного средства | |
| BR122021002471B8 (pt) | Dispositivo de distribuição de droga nasal | |
| WO2014012069A3 (en) | Dry powder drug delivery systems and methods | |
| CL2013000153A1 (es) | Metodo para entregar una solucion de un medicamento a un ojo de un sujeto que lo necesita, comprende, el proveer gotitas que contienen dicho medicamento, en donde dichas gotitas tienen un tamaño promedio de gotita por lo menos de aproximadamente 15 micrones y una velocidad de eyeccion inicial promedio entre 1 m/s y 5 m/s, y entregar dicho medicamento a dicho ojo, donde entre aproximadamente 80% y 100% de la masa de dichas gotitas es depositado en el ojo. | |
| MY191380A (en) | Stabilized fixed dose drug composition having mometasone and olopatadine | |
| EP4574191A3 (en) | Pulmonary delivery devices | |
| ATE527976T1 (de) | Vorrichtung zur lagerung, unmittelbaren zubereitung und verabreichung eines wirkstoffes | |
| MY196072A (en) | Liquid Inhalation Formulation Comprising RPL554 | |
| EA201591869A1 (ru) | Композиция, содержащая для повышения стабильности лекарственной формы по меньшей мере два сухих порошка, получаемых распылительной сушкой | |
| JP2020527377A5 (enExample) | ||
| EA201700182A1 (ru) | Состав для повышения стабильности лекарственного препарата, содержащий по меньшей мере один сухой порошок, полученный распылительной сушкой | |
| MX2016007181A (es) | Medicamentos inhalables. | |
| MD20160061A2 (ro) | Sistem de livrare a medicamentului compus din particule multiple | |
| CA2991760C (en) | DRY INHALATION POWDER FORMULATIONS | |
| HK1215167A1 (zh) | 可吸入药用组合物和含有该药用组合物的吸入器装置 |